Microsoft, other blue chip stocks rebound as biotech slide continues
NEW YORK — Stocks pushed mostly higher on Friday for the first time in three days.
The gains were modest as investors continued to cut their holdings in biotechnology stocks, some of the best performers of 2013. Instead, the stocks that advanced the most were mostly mature, large companies such as Microsoft, Exxon and Cisco Systems.
The Dow Jones industrial average rose 58.83 points, or 0.4 percent, to 16,323.06. The Standard & Poor's 500 index rose 8.58 points, or 0.5 percent, to 1,857.62. The Nasdaq composite, which includes a number of large biotech companies, rose 4.53 points, or 0.1 percent, to 4,155.76.
The biggest gainer in the Dow was Microsoft, which rose 94 cents, or 2.4 percent, to $40.30. The company announced Thursday that it is bringing Microsoft Office to the iPad and will shift its focus away from Windows, a move that analysts liked.
“We continue to view (Office on the iPad) as a massive revenue and operating profit opportunity for Microsoft,” analysts at Credit Suisse said in a report Thursday.
Microsoft helped lift other large technology companies, with Cisco Systems, Intel and Oracle up roughly 1 percent or more.
In contrast to technology, biotechnology had another horrible day. Gilead Sciences, Biogen Idec and Vertex Pharmaceuticals were all down 4 percent or more.
The higher they rise, the harder they fall, investors say. Biotechnology stocks had been among the hottest sectors in the stock market for the last two years, with the S&P 500 Biotechnology index rising 74 percent in 2013 and 38 percent in 2012.
That momentum stopped dead in the month of March. The S&P 500 Biotechnology index is down 12 percent this month alone, erasing all of the sector's gains in January and February.
The sell-off in biotech echoes the pullback investors have seen in speculative technology stocks, such as Twitter, Netflix and Tesla Motors. Those stocks are down between 14 percent and 20 percent this month alone.
“The high-momentum names have lost all the traction they had in the past year,” said John Fox, director of research at Fenimore Asset Management.
Investors will now turn their attention to next week's economic data, including the March jobs report due out Friday. Economists expect the U.S. economy, thawing from the harsh winter, created 200,000 jobs last month and the unemployment rate remained steady at 6.6 percent.
In other markets, the yield on the 10-year Treasury note hovered around 2.72 percent, up from 2.69 percent Thursday. The price of crude oil edged up 39 cents, or 0.4 percent, to $101.67 a barrel. Gold was little changed at $1,293.80 an ounce.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Airlines offer small conveniences to counter higher fees, less space
- Aetna to buy rival Humana for $35B
- Consider these factors before opting for longer-term auto loan
- Longer, roomier, ritzier Sedona upgrades minivan to 1st-class
- McDonald’s localizes menus to battle growing competition
- Air control stickiness a real puzzler
- National Day Calendar lends legitimacy to pseudo-holidays
- Insurer Aetna to buy Humana in $35B deal
- Facebook lures premium content from YouTube
- U.S. employers add 223K jobs, jobless rate falls to 5.3%
- Critics find hotels’ hidden fees to be inhospitable